DICE
NASDAQDICE Therapeutics Inc.
This company no longer trades as DICE. The ticker now belongs to a fund, Tema ETF Trust Tema Trading & Prediction Markets ETF.
DICE Therapeutics Inc. (DICE) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for DICE in the last 30 days. The most recent was published Aug 21, 2023.
Latest news
25 items- SECSEC Form 15-12G filed by DICE Therapeutics Inc.15-12G - DICE Therapeutics, Inc. (0001645569) (Filer)
- SECSEC Form EFFECT filed by DICE Therapeutics Inc.EFFECT - DICE Therapeutics, Inc. (0001645569) (Filer)
- INSIDERSEC Form 4 filed by Ra Capital Management, L.P.4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- 13D/GSEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)SC 13D/A - DICE Therapeutics, Inc. (0001645569) (Subject)
- INSIDERSEC Form 4: Tetlow Sharon returned 49,841 shares to the company, closing all direct ownership in the company4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- INSIDERSEC Form 4 filed by Simson Jake4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- INSIDERSEC Form 4: Scopa James Paul returned 40,921 shares to the company, closing all direct ownership in the company4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- INSIDERSEC Form 4: Robertson Scott M. returned 198,000 shares to the company, closing all direct ownership in the company4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- INSIDERSEC Form 4: Scheller Richard H returned 8,427 shares to the company, closing all direct ownership in the company4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- INSIDERSEC Form 4: Timothy Lu returned 152,285 shares to the company, closing all direct ownership in the company4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- INSIDERSEC Form 4: Judice Kevin returned 799,685 shares to the company, closing all direct ownership in the company4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- INSIDERSEC Form 4: Jacobsen John R. returned 147,497 shares to the company, closing all direct ownership in the company4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- INSIDERSEC Form 4 filed by Doyle Mittie4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- INSIDERSEC Form 4 filed by Bowers Lisa4 - DICE Therapeutics, Inc. (0001645569) (Issuer)
- NEWSWhat 9 Analyst Ratings Have To Say About DICE TherapeuticsAnalysts have provided the following ratings for DICE Therapeutics (NASDAQ:DICE) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 7 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 5 0 0 3M Ago 2 0 1 0 0 These 9 analysts have an average price target of $50.78 versus the current price of DICE Therapeutics at $47.55, implying upside. Below is a summary of how these 9 analysts rated DICE Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock This current av
- SECSEC Form S-8 POS filed by DICE Therapeutics Inc.S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)
- SECSEC Form S-8 POS filed by DICE Therapeutics Inc.S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)
- SECSEC Form S-8 POS filed by DICE Therapeutics Inc.S-8 POS - DICE Therapeutics, Inc. (0001645569) (Filer)
- SECSEC Form POSASR filed by DICE Therapeutics Inc.POSASR - DICE Therapeutics, Inc. (0001645569) (Filer)
- SECSEC Form POS AM filed by DICE Therapeutics Inc.POS AM - DICE Therapeutics, Inc. (0001645569) (Filer)
- SECDICE Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - DICE Therapeutics, Inc. (0001645569) (Filer)
- SECSEC Form SC 14D9/A filed by DICE Therapeutics Inc. (Amendment)SC 14D9/A - DICE Therapeutics, Inc. (0001645569) (Subject)
- SECSEC Form SC TO-T/A filed by DICE Therapeutics Inc. (Amendment)SC TO-T/A - DICE Therapeutics, Inc. (0001645569) (Subject)
- PRLilly Completes Acquisition of DICE TherapeuticsINDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ:DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology. "Since our founding nearly 150 years ago, we've strived to make life better for people around the world – but we know that to achieve this goal, we have to bring the brightest minds to Lilly," said Ajay Nirula, Ph.D., senior vice president of immunology at Lilly. "With the passion and expertise of our new
- SECSEC Form 25-NSE filed by DICE Therapeutics Inc.25-NSE - DICE Therapeutics, Inc. (0001645569) (Subject)
DICE FAQ
7 questionsWhat is the latest news on DICE?
Quantisnow has not tracked any new filings, ratings or press releases for DICE in the last 30 days. The most recent wire item was published on August 21, 2023.Where does DICE stock trade?
DICE Therapeutics Inc. (DICE) is listed on NASDAQ.What sector and industry is DICE in?
DICE Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did DICE Therapeutics Inc. go public?
DICE Therapeutics Inc. (DICE) completed its IPO in 2021.What are analysts saying about DICE?
DICE Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Equal Weight with a $38.00 price target on 2023-05-24. Recent price targets range from $36.00 to $71.00.What companies are similar to DICE?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare DICE side-by-side with any of them on Quantisnow.How can I track DICE on Quantisnow?
Quantisnow aggregates DICE Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DICE to receive live email and push alerts on every new disclosure.